| 2.94 -0.07 (-2.33%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.01  |
1-year : | 4.53 |
| Resists | First : | 3.44 |
Second : | 3.88 |
| Pivot price | 3.34 |
|||
| Supports | First : | 2.73 |
Second : | 2.27 |
| MAs | MA(5) : | 3.07 |
MA(20) : | 3.3 |
| MA(100) : | 2.24 |
MA(250) : | 1.84 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 3.3 |
D(3) : | 8.4 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 3.88 | Low : | 1.18 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MGNX ] has closed above bottom band by 0.3%. Bollinger Bands are 26.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3 - 3.03 | 3.03 - 3.04 |
| Low: | 2.85 - 2.88 | 2.88 - 2.9 |
| Close: | 2.9 - 2.95 | 2.95 - 2.97 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Wed, 29 Apr 2026
MacroGenics (MGNX) price target increased by 50.00% to 6.12 - MSN
Tue, 21 Apr 2026
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fri, 17 Apr 2026
B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity - Yahoo Finance
Fri, 10 Apr 2026
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble (MGNX) - Seeking Alpha
Thu, 09 Apr 2026
MacroGenics gains removal of FDA partial hold on lead program - Seeking Alpha
Wed, 08 Apr 2026
MacroGenics can enroll new cancer patients after FDA lifts study hold - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 64.5 (%) |
| Shares Short | 3,780 (K) |
| Shares Short P.Month | 4,090 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | -50 % |
| Operating Margin | -29.4 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | -87 % |
| Qtrly Rev. Growth | 113 % |
| Gross Profit (p.s.) | -0.53 |
| Sales Per Share | 2.35 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -2.5 |
| PEG Ratio | 0 |
| Price to Book value | 3.34 |
| Price to Sales | 1.24 |
| Price to Cash Flow | -2.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|